73110-52-8

Upstream product

• 100-06-1 1-(4-methoxyphenyl)ethanone 
• 1761-61-1 5-bromosalicyclaldehyde 
• 2632-13-5 2-Bromo-4'-methoxyacetophenone 
• 1777-55-5 (4-methoxyphenacylidene)triphenyl phosphorane 
• 90-59-5 3,5-Dibromosalicylaldehyde 

Downstream Products

• 1537909-53-7 C₂₃H₁₄BrF₃N₂O₇ 
• 1537909-67-3 C₂₃H₁₆BrF₃N₄O₆ 
• 1435462-22-8 1-(5-(5-bromo-2-(2,6-dinitro-4-(trifluoromethyl)-phenoxy)phenyl)-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)ethanone 
• 126985-03-3 C₁₈H₁₇BrN₂O₃ 
• 496771-90-5 C₁₆H₁₅BrN₂O₂ 

Relevant academic research and scientific papers

Synthesis of (Het)aryl 2-(2-hydroxyaryl)cyclopropyl ketones

A simple general method for the synthesis of 1-acyl-2-(ortho-hydroxyaryl)cyclopropanes, which belong to the donor–acceptor cyclopropane family, has been developed. This method, based on the Corey–Chaykovsky cyclopropanation of 2-hydroxychalcones, allows f

Novel hybrids derived from aspirin and chalcones potently suppress colorectal cancer in vitro and in vivo

Colorectal cancer (CRC) remains the fourth leading cause of cancer deaths around the world despite the availability of many approved small molecules for treatment. The issues lie in the potency, selectivity and targeting of these compounds. Therefore, new

Novel tricyclic pyrazolo[1,5-d][1,4]benzoxazepin-5(6H)-one: Design, synthesis, model and use as hMAO-B inhibitors

Based on our recently reported selective hMAO-A inhibitors, on which, the intramolecular cyclization led to a very interesting change of isoform selectivity. A series of selective hMAO-B inhibitors (3a-3u) with novel scaffold of tricyclic pyrazolo[1,5-d][1,4]benzoxazepin-5(6H)-one were designed and synthesized. Compound 3u (IC50 = 221 nM) exhibited the best inhibitory activity and isoform selectivity against hMAO-B, superior to selegiline (IC50 = 321 nM), which is a commercial selective hMAO-B inhibitor used to Parkinson's disease. Modeling study indicated that the selectivity of our compounds to hMAO-B is determined by at least two residues, i.e., Ile 199 and Cys 172 (or corresponded Phe 208 and Asn 181 of hMAO-A). These data support further studies to assess rational design of more efficiently selective hMAO-B inhibitors.

Synthesis, characterization, antimicrobial and phytotoxic screening of 1-aroyl-3,5-diarylpyrazoline derivatives

Pyrazolines are biologically and pharmaceutically very active scaffolds. Derivatives of (3,5-diphenyl-4,5-dihydro-1H-pyrazol-1-yl)(phenyl)methanone were synthesized by the cyclization of chalcones (1a-c) with substituted benzyl hydrazides (2a-e) using a f

Synthesis, and antibacterial activity of novel 4,5-dihydro-1H-pyrazole derivatives as DNA gyrase inhibitors

A series of novel 4,5-dihydropyrazole derivatives (4a-4t), containing the dinitrobenzotrifluoride moiety, as DNA gyrase inhibitors were designed and synthesized. Based on the preliminary results, compounds 4d, 4h and 4t with potent inhibitory activity in

Synthesis, biological evaluation of novel 4,5-dihydro-2H-pyrazole 2-hydroxyphenyl derivatives as BRAF inhibitors

A series of novel 4,5-dihydropyrazole derivatives (3a-3t) containing hydroxyphenyl moiety as potential V600E mutant BRAF kinase (BRAF V600E) inhibitors were designed and synthesized. Docking simulation was performed to insert compounds 3d (1-(5-(5-chloro-2-hydroxyphenyl)-3-(p- tolyl)-4,5-dihydro-1H-pyrazol-1-yl)ethanone) and 3m (1-(3-(4-chlorophenyl)-5-(3, 5-dibromo-2-hydroxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)ethanone) into the crystal structure of BRAFV600E to determine the probable binding model, respectively. Based on the preliminary results, compound 3d and 3m with potent inhibitory activity in tumor growth may be a potential anticancer agent. Results of the bioassays against BRAFV600E, MCF-7 human breast cancer cell line and WM266.4 human melanoma cell line all showed several compounds had potent activities IC50 value in low micromolar range, among them, compound 3d and compound 3m showed strong potent anticancer activity, which were proved by that 3d: IC50 = 1.31 μM for MCF-7 and IC50 = 0.45 μM for WM266.5, IC50 = 0.22 μM for BRAFV600E, 3m: IC50 = 0.97 μM for MCF-7 and IC50 = 0.72 μM for WM266.5, IC50 = 0.46 μM for BRAFV600E, which were comparable with the positive control Erlotinib.

Retrochalcone derivatives are positive allosteric modulators at synaptic and extrasynaptic GABAA receptors in vitro

BACKGROUND AND PURPOSE Flavonoids, important plant pigments, have been shown to allosterically modulate brain GABAA receptors (GABA ARs). We previously reported that trans-6,4′- dimethoxyretrochalcone (Rc-OMe), a hydrolytic derivative of the corresponding flavylium salt, displayed nanomolar affinity for the benzodiazepine binding site of GABAARs. Here, we evaluate the functional modulations of Rc-OMe, along with two other synthetic derivatives trans-6-bromo-4′- methoxyretrochalcone (Rc-Br) and 4,3′-dimethoxychalcone (Ch-OMe) on GABAARs. EXPERIMENTAL APPROACH Whole-cell patch-clamp recordings were made to determine the effects of these derivatives on GABAARs expressed in HEK-293 cells and in hippocampal CA1 pyramidal and thalamic neurones from rat brain. KEY RESULTS Rc-OMe strongly potentiated GABA-evoked currents at recombinant α 1-4β2γ2s and α 4β3I receptors but much less at α1β2 and α4β3. Rc-Br and Ch-OMe potentiated GABA-evoked currents at α1β 2γ2s. The potentiation by Rc-OMe was only reduced at α1H101Rβ2γ2s and α1β2N265Sγ2s, mutations known to abolish the potentiation by diazepam and loreclezole respectively. The modulation of Rc-OMe and pentobarbital as well as by Rc-OMe and the neurosteroid 3α,21-dihydroxy-5α-pregnan-20-one was supra-additive. Rc-OMe modulation exhibited no apparent voltage-dependence, but was markedly dependent on GABA concentration. In neurones, Rc-Br slowed the decay of spontaneous inhibitory postsynaptic currents and both Rc-OMe and Rc-Br positively modulated synaptic and extrasynaptic diazepam-insensitive GABAARs. CONCLUSIONS AND IMPLICATIONS The trans-retrochalcones are powerful positive allosteric modulators of synaptic and extrasynaptic GABAARs. These novel modulators act through an original mode, thus making them putative drug candidates in the treatment of GABAA-related disorders in vivo.

Amino-substituted flavans useful as anti-viral agents

Novel compounds of formula (IID) STR1 wherein either both X and Y represent groups independently selected from amino and lower alkylamino, or one of X and Y represents a group selected from amino and lower alkylamino and the other of X and Y represents a hydrogen atom have been found to be active against rhinoviruses and other viruses. Processes for producing these compounds include reduction of flavanone derivatives or of flavenes. Alternatively, reductive cyclization of chalcones affords the compounds. These may also be prepared by condensation of o-(substituted methyl)phenols with styrene derivatives. Pharmaceutical formulations and methods for the administration of the compounds are described.